Georg Schroeckenfuchs – President MEA and Head Gulf & Saudi Country Group, Novartis

Georg Schroeckenfuchs, Novartis’ president MEA and head of its Gulf and Saudi Country Group, explains how the company’s objectives are aligned with Saudi Arabia’s Vision 2030, the progress made towards the nationalization of its Saudi workforce, the potential impact of changes in the tender process, and why Novartis is uniquely positioned to build on Saudi Arabia’s clinical trial capabilities.  
The ambitious mindset that the Saudi Arabia Vision 2030 sets out fits well with the mentality we are embracing at Novartis. I like to say that we shoot for the moon, and even if we miss, we will land among the stars
Become a PharmaBoardroom Member for free to access this content
Join the 35,000+ pharmaceutical professionals who already subscribe to PharmaBoardroom
Already a member? Sign In

Related Interviews

Latest Report